Physician profile
Harsh Patel
NPI 1558723932
$5,549.24
in general payments reported to CMS, 2019-2025
32 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $423 · 2022: $450 · 2023: $1,357 · 2024: $1,556 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264 · Education: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.98 |
| Education | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,353.30 | 2020-2025 | |
| Janssen Biotech, INC. | $916.64 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Olympus Corporation of The Americas | $539.78 | 2019-2020 | |
| Genzyme Corporation | $395.71 | 2023-2025 | |
| Medtronic, INC. | $289.27 | 2022-2024 | Endoflip, Interstim, Nexpowder |
| Phathom Pharmaceuticals, INC. | $255.08 | 2024 | Voquezna |
| Abbott Laboratories | $245.65 | 2022-2025 | Mitraclip, Navitor |
| Pfizer INC. | $156.11 | 2023-2025 | |
| Madrigal Pharmaceuticals | $153.89 | 2024-2025 | Resmetirom, Rezdiffra |
| Medical Device Business Services, INC. | $147.58 | 2023 | Linx Reflux Management System |
| Axonics, INC. | $146.99 | 2023-2024 | Axonics |
| Boston Scientific Corporation | $120.19 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $111.37 | 2023-2024 | Idacio |
| Janssen Scientific Affairs, LLC | $96.52 | 2022 | |
| Aimmune Therapeutics, INC. | $71.28 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $68.96 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $59.04 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $52.41 | 2022-2023 | Dificid, Prevymis, Zerbaxa |
| Novo Nordisk INC | $48.16 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.31 | 2022-2023 | Trulance |
| Teleflex LLC | $32.86 | 2024 | Solesta |
| Shire North American Group INC | $31.96 | 2019 | |
| Celltrion USA INC. | $26.86 | 2024 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $24.19 | 2024 | Entyvio |
| Vivus LLC | $24.12 | 2024 | Pancreaze |
| Braintree Laboratories, INC. | $23.95 | 2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $23.56 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $23.44 | 2024 | |
| Lucid Diagnostics INC. | $22.97 | 2023 | |
| Janssen Pharmaceuticals, INC | $18.65 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.60 | 2024 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.84 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.